Table 3 The efficacy of endostar with NSCLC in previously reported studies

Zhai  et al.

67

III

60-66Gy/30–33F, 5 times /week

50 mg/m²/d of cisplatin on days 1, 8, 29, and 36 plus 50 mg/m²/d of etoposide on days 1–5 and days 29–33

7.5 mg/m²/day for 5 days before the beginning of RT, repeated at week 2, 4, and 6 during RT

grade≥ 2 RP 11.9%

1, 2, and 3-year

PFS were 50.7%, 34.8%, and 28.2%

1, 2, and 3-year OS were 82.1%, 59.9% and 47.7%

Endostar had a better OS, promising 2year-PFS with acceptable toxicity

[8]

Ma  et al.

193

III

2Gy/F/day,

5times /week

etoposide + cisplatin 50mg/m² ; DP/C 65mg/m² or carboplatin AUC =5;

TP/C 135–175mg/m²,65mg/m² or carboplatin AUC=5;

NP/C 60mg/m²,65mg/m²;

AP/C 500mg/m²,65mg/m²;

GP/C 1000mg/m²,65mg/m²;

repeated every 4 weeks

7.5 mg/m²/day with 5–7 days

(Endostar) late-stage 1 grade lung injury-14.4%, late-stage 2 grade lung injury-3.80%;

(non-Endostar) late-stage 1 grade lung injury-33.7%; late-stage 2 grade lung injury-9.10%;(P=0.02)

NR

(Endostar) the mOS-29.7m 5year OS rate-34.7%;(non-Endostar)the mOS-21.3m

5year OS rate-23.6%;(P=0.038)

Endostar improved mOS and 5-year survival rate, reduced the toxic and side effects

[13]

Sun et.al

19

III

60-66Gy/30–33F,5 times /week

chemotherapy consisting of weekly 50 mg/m² paclitaxel over 1 h, weekly 2 mg/mL/min carboplatin over 30 min

7.5 mg/m² endostatin over 3h infusion between days 1 and 14 and between days 22 and 35

26 % had grade 3 RP

mPFS was 10.0m (95%CI:7.6-12.3m)

mOS was 14.0m (95% CI:10.7–17.2m)

endostatin's influence on NSCLC patient survival remains unknown, with unacceptable toxicity

[14]

Bao et.al

48

III

60-66Gy/30–33F for 6 -7 weeks

two doses of docetaxel(65 mg/m²) and cisplatin (65 mg/m²) on days 8 and 36

7.5mg/m²/d was administered over 4 h each day for 7 days at weeks 1, 3, 5, and 7

grade≥ 2 RP 25% grade> 3 RP 12%

1-, 2-, and 3year PFS rates were 48%, 27%, and 16%

1-, 2-, and 3year OS rates were 81%, 50%, and 30%

Endostar with CCRT for LA-NSCLC patients promises short-term effect and local control rates

[15]

Zhu et.al

75

III and IV

PCTV60–66Gy/30–33F/6–7 weeks for stage III,

PGTV54–60Gy/27–30F/5.5–6 weeks for stage IV

NR

210mg total, continuous infusion for 5–7 days via micropump every 3 weeks

Endostar group exhibited a numerically lower rate of RP relapse, RP death and pulmonary fibrosis

mPFS was 8.0 and 4.4m (HR:0.53; 95% CI: 0.32–0.90; p = 0.019) for Endostar and non-Endostar groups

mOS was 40.0 and 13.1m (HR: 0.53; 95% CI: 0.28–0.98; p = 0.045) for Endostar and non-Endostar groups

endostatin showed better survival outcomes and a tendency toward fewer radiation-related pulmonary events in NSCLC patients

[7]